These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 32356420

  • 1. Fecal Calprotectin as a Useful Non-Invasive Screening Marker for Eosinophilic Gastrointestinal Disorder in Korean Children.
    Yoo IH, Cho JM, Joo JY, Yang HR.
    J Korean Med Sci; 2020 May 04; 35(17):e120. PubMed ID: 32356420
    [Abstract] [Full Text] [Related]

  • 2. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
    Holtman GA, Lisman-van Leeuwen Y, Kollen BJ, Norbruis OF, Escher JC, Kindermann A, de Rijke YB, van Rheenen PF, Berger MY.
    Ann Fam Med; 2016 Sep 04; 14(5):437-45. PubMed ID: 27621160
    [Abstract] [Full Text] [Related]

  • 3. Noninvasive testing in the management of children with suspected inflammatory bowel disease.
    Dilillo D, Zuccotti GV, Galli E, Meneghin F, Dell'Era A, Penagini F, Colella G, Lewindon P, Carmagnola S, Farina E, Ardizzone S, Maconi G.
    Scand J Gastroenterol; 2019 May 04; 54(5):586-591. PubMed ID: 31032665
    [Abstract] [Full Text] [Related]

  • 4. Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children.
    Teng X, Gao C, Sun M, Wu J.
    Clin Rheumatol; 2018 Jun 04; 37(6):1667-1673. PubMed ID: 29018973
    [Abstract] [Full Text] [Related]

  • 5. Fecal calprotectin levels in children is more tightly associated with histological than with macroscopic endoscopy findings.
    Hradsky O, Ohem J, Mitrova K, Durilova M, Kotalova R, Nevoral J, Kolho KL, Bronsky J.
    Clin Lab; 2014 Jun 04; 60(12):1993-2000. PubMed ID: 25651733
    [Abstract] [Full Text] [Related]

  • 6. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
    Samant H, Desai D, Abraham P, Joshi A, Gupta T, Dherai A, Ashavaid T.
    Indian J Gastroenterol; 2015 Nov 04; 34(6):431-5. PubMed ID: 26589229
    [Abstract] [Full Text] [Related]

  • 7. Predicting inflammatory bowel disease in children with abdominal pain and diarrhoea: calgranulin-C versus calprotectin stool tests.
    Heida A, Van de Vijver E, van Ravenzwaaij D, Van Biervliet S, Hummel TZ, Yuksel Z, Gonera-de Jong G, Schulenberg R, Muller Kobold A, van Rheenen PF, CACATU consortium.
    Arch Dis Child; 2018 Jun 04; 103(6):565-571. PubMed ID: 29514815
    [Abstract] [Full Text] [Related]

  • 8. The combination of fecal calprotectin with ESR, CRP and albumin discriminates more accurately children with Crohn's disease.
    Daniluk U, Daniluk J, Krasnodebska M, Lotowska JM, Sobaniec-Lotowska ME, Lebensztejn DM.
    Adv Med Sci; 2019 Mar 04; 64(1):9-14. PubMed ID: 30237086
    [Abstract] [Full Text] [Related]

  • 9. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children.
    Sidler MA, Leach ST, Day AS.
    Inflamm Bowel Dis; 2008 Mar 04; 14(3):359-66. PubMed ID: 18050298
    [Abstract] [Full Text] [Related]

  • 10. Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn's disease.
    E Penna FGC, Rosa RM, da Cunha PFS, de Souza SCS, de Abreu Ferrari ML.
    BMC Gastroenterol; 2020 Feb 13; 20(1):35. PubMed ID: 32054445
    [Abstract] [Full Text] [Related]

  • 11. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
    Nancey S, Boschetti G, Moussata D, Cotte E, Peyras J, Cuerq C, Haybrard J, Charlois AL, Mialon A, Chauvenet M, Stroeymeyt K, Kaiserlian D, Drai J, Flourié B.
    Inflamm Bowel Dis; 2013 Apr 13; 19(5):1043-52. PubMed ID: 23511035
    [Abstract] [Full Text] [Related]

  • 12. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability.
    Padoan A, D'Incà R, Scapellato ML, De Bastiani R, Caccaro R, Mescoli C, Moz S, Bozzato D, Zambon CF, Lorenzon G, Rugge M, Plebani M, Basso D.
    Clin Chem Lab Med; 2018 Oct 25; 56(11):1926-1935. PubMed ID: 29729144
    [Abstract] [Full Text] [Related]

  • 13. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
    Canani RB, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R.
    Dig Liver Dis; 2008 Jul 25; 40(7):547-53. PubMed ID: 18358796
    [Abstract] [Full Text] [Related]

  • 14. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay.
    Diamanti A, Panetta F, Basso MS, Forgione A, Colistro F, Bracci F, Papadatou B, Francalanci P, Torroni F, Knafelz D, Fina F, Castro M.
    Inflamm Bowel Dis; 2010 Nov 25; 16(11):1926-30. PubMed ID: 20310017
    [Abstract] [Full Text] [Related]

  • 15. Fecal Calprotectin as a Screening Marker for Inflammatory Bowel Disease.
    Sridhar M, Kesavelu D.
    Indian Pediatr; 2019 Mar 15; 56(3):249-250. PubMed ID: 30955002
    [Abstract] [Full Text] [Related]

  • 16. Clinical Evaluation of Inflammatory and Blood Parameters in the Workup of Pediatric Chronic Abdominal Pain.
    Zeevenhooven J, Rexwinkel R, Tromp E, Haver B, Groeneweg M, Benninga MA, Vlieger AM.
    J Pediatr; 2020 Apr 15; 219():76-82.e3. PubMed ID: 31987658
    [Abstract] [Full Text] [Related]

  • 17. Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.
    Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S.
    Inflamm Bowel Dis; 2017 Nov 15; 23(11):2048-2053. PubMed ID: 28945636
    [Abstract] [Full Text] [Related]

  • 18. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
    Dolinšek J, Rižnik P, Sabath L, Mičetić-Turk D.
    Wien Klin Wochenschr; 2016 Apr 15; 128(7-8):253-9. PubMed ID: 26659704
    [Abstract] [Full Text] [Related]

  • 19. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease.
    Abej E, El-Matary W, Singh H, Bernstein CN.
    Can J Gastroenterol Hepatol; 2016 Apr 15; 2016():2483261. PubMed ID: 27774443
    [Abstract] [Full Text] [Related]

  • 20. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
    Chang MH, Chou JW, Chen SM, Tsai MC, Sun YS, Lin CC, Lin CP.
    Mol Med Rep; 2014 Jul 15; 10(1):522-6. PubMed ID: 24788223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.